Key facts
- This page summarizes Everett Rand Sutherland's Form 4 filing for Krystal Biotech, Inc. (KRYS).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 31 Jan 2022, 15:47.
Everett Rand Sutherland - 31 Jan 2022 Form 4 Insider Report for Krystal Biotech, Inc. (KRYS)
- Reporting relationship
- Director
- Issuer ticker
- KRYS
- Reported as of
- 31 Jan 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 31 Jan 2022, 15:47:06 UTC
- Prior SEC filing
- 26 Jan 2022
- Next SEC filing
- 01 Jul 2022
- Source filing
- View source filing
- Reporting owner signature
- Krish Krishnan, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Everett Rand Sutherland filed Form 4 for Krystal Biotech, Inc. (KRYS) on 31 Jan 2022.
Change
- Previous filing in this sequence was filed on 26 Jan 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KRYS
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +13,600
- Change %
- Price
- $0.000000
- Shares after
- 13,600
- Date
- 31 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 13,600
- Exercise price
- $59.00
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The options were awarded on January 31, 2022 and vest in equal monthly tranches over a three-year period.